Dispatch Biotherapeutics Inc. is taking aim at solid tumors with a new viral vector/antigen technology backed by major industry names such as Arch Venture Partners and Bristol Myers Squibb Co. With ...

DelveInsight's Claudin 18.2 Directed Therapies Market Size, Target Population, Competitive Landscape & Market Forecast report ...